Monitor the offering's pricing and final size upon completion; the stock may trade lower on dilution despite positive clinical data. Watch for lock-up expiry (60 days) and potential insider selling. Evaluate the company's cash runway after the raise relative to Phase 3 cost estimates.
Price Chart
Executive Summary
Avalo Therapeutics filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-funded warrants, the size and pricing of which remain undisclosed. The offering follows the announcement of positive Phase 2 LOTUS trial results for lead asset abdakibart in hidradenitis suppurativa, with proceeds intended to fund Phase 3 development. The dilutive capital raise offsets the positive clinical milestone, creating a mixed outlook.
Key Facts
- Positive Phase 2 LOTUS topline data announced May 5, 2026: HiSCR75 met primary endpoint at both doses (p<0.02), with 42.5% combined absolute improvement over placebo.
- Offering consists of common stock and pre-funded warrants (exercise price $0.001); share count and pricing not yet disclosed.
- Pro forma cash, cash equivalents, and short-term investments of approximately $82.0 million as of March 31, 2026 (preliminary).
- Stock closed at $13.78 on May 4, 2026; market cap ~$368M.
- Proceeds will fund abdakibart Phase 3 development and general corporate purposes.
Financial Impact
Undisclosed offering size; dilution will be significant relative to current market cap given $82M cash base and clinical-stage status.
Risk Factors
- Substantial dilution from the offering and potential future capital needs.
- Phase 3 development delay or failure could impair value.
- No public market for pre-funded warrants limits liquidity for those instruments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-055665 |
| Document: 0001104659-26-055665-index-headers.html | 0001104659-26-055665 |
| Document: 0001104659-26-055665-index.html | 0001104659-26-055665 |
| Document: 0001104659-26-055665.txt | 0001104659-26-055665 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | $14.99 (−27.76%) |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | $14.99 (−24.86%) |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | $14.99 (−19.84%) |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | $14.99 (+16.20%) |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access